By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
SECUADO Drug Profile
Email this page to a colleague
Which patents cover Secuado, and what generic alternatives are available?
Secuado is a drug marketed by Hisamitsu and is included in one NDA. There are four patents protecting this drug.
This drug has thirty-eight patent family members in nine countries.
The generic ingredient in SECUADO is asenapine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the asenapine profile page.
DrugPatentWatch® Generic Entry Outlook for Secuado
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 25, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for SECUADO
| International Patents: | 38 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in SECUADO? | SECUADO excipients list |
| DailyMed Link: | SECUADO at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for SECUADO
Generic Entry Date for SECUADO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SYSTEM;TRANSDERMAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for SECUADO
| Drug Class | Atypical Antipsychotic |
ATC Classes for SECUADO
US Patents and Regulatory Information for SECUADO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-001 | Oct 11, 2019 | RX | Yes | No | Get Started Free | Get Started Free | Y | Get Started Free | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-002 | Oct 11, 2019 | RX | Yes | No | Get Started Free | Get Started Free | Y | Get Started Free | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-001 | Oct 11, 2019 | RX | Yes | No | Get Started Free | Get Started Free | Y | Get Started Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SECUADO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201410270 | Get Started Free |
| Japan | 6005741 | Get Started Free |
| World Intellectual Property Organization (WIPO) | 2014017593 | Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for SECUADO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0746317 | SPC/GB10/046 | United Kingdom | Get Started Free | PRODUCT NAME: ASENAPINE; REGISTERED: UK EU/1/10/640/001 20100901; UK EU/1/10/640/002 20100901; UK EU/1/10/640/003 20100901; UK EU/1/10/640/004 20100901; UK EU/1/10/640/005 20100901; UK EU/1/10/640/006 20100901 |
| 0746317 | 10C0056 | France | Get Started Free | PRODUCT NAME: ASENAPINE; REGISTRATION NO/DATE: EU/1/10/640/001 20100901 |
| 0746317 | C300461 | Netherlands | Get Started Free | PRODUCT NAME: ASENAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MALEAAT; REGISTRATION NO/DATE: EU/1/10/640/001-006 20100901 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
